Innovent receives NMPA approval for Taletrectinib Adipate capsule from NMPA
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Strategic focus on COCO-model with a nationwide reach of 501 stores
Krsnaa Diagnostics receives LoI from RINPAS for radiology services
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated